India-based Bharat Biotech has entered into an exclusive agreement to develop a Covid-19 vaccine candidate created at Thomas Jefferson University in Philadelphia, US.
Infectious Diseases expert professor Matthias Schnell’s lab created the vaccine candidate in January using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.
This approach, used as a vehicle or carrier vaccine, is known to generate a strong immune response, authorised for the whole population, including children and pregnant women.
In preliminary tests in animal models, the vaccine demonstrated a strong antibody response in mice. Currently, the researchers are evaluating if vaccinated animals are protected from Covid-19 infection and results are